Stocks and Investing Stocks and Investing
Mon, October 2, 2017
[ 12:00 AM ] - WOPRAI
Gregg Moskowitz Downgraded (APPN) to Hold on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
David George Downgraded (ZION) to Sell on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Rajeev Lalwani Maintained (AAL) at Hold with Increased Target to $51 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
David Hochstim Initiated (AXP) at Hold and Held Target at $92 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Brian Meredith Maintained (AXS) at Strong Sell with Decreased Target to $55 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
James Naklicki Maintained (AXS) at Hold with Decreased Target to $58 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Manav Patnaik Maintained (BFAM) at Buy with Increased Target to $90 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
James Naklicki Maintained (ALL) at Strong Buy with Decreased Target to $106 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Terence Flynn Upgraded (ALNY) to Strong Buy on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Nicholas Yulico Maintained (VTR) at Hold with Decreased Target to $66 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Shneur Gershuni Initiated (VNOM) at Hold and Held Target at $18 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Kaimon Chung Initiated (VIRT) at Hold and Held Target at $17 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Tristan Gerra Downgraded (WDC) to Hold on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Brandon Oglenski Maintained (WERN) at Hold with Increased Target to $32 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Nigel Coe Maintained (WCC) at Buy with Increased Target to $70 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Michael Weinstein Maintained (BKH) at Buy with Increased Target to $77 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Matthew Harrison Downgraded (BLUE) to Sell on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Michael Lasser Downgraded (TSCO) to Hold on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
James Naklicki Maintained (TRV) at Strong Buy with Decreased Target to $140 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Brian Nowak Upgraded (TRUE) to Hold on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Prashant Rao Maintained (TRN) at Strong Buy with Increased Target to $45 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Matthew Brooklier Maintained (TRN) at Strong Buy with Increased Target to $36 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Christian Schwab Upgraded (STX) to Strong Buy on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Nigel Coe Upgraded (SWK) to Buy on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Andrew Boone Initiated (TTD) at Buy and Held Target at $7 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Robert Moskow Maintained (TSN) at Hold with Increased Target to $75 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Benjamin Theurer Maintained (TSN) at Buy with Increased Target to $80 on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Ravi Shanker Downgraded (UNP) to Hold on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Philip Cusick Downgraded (UNIT) to Hold on, Oct 2nd, 2017
[ 12:00 AM ] - WOPRAI
Matthew Harrison Upgraded (SRPT) to Buy on, Oct 2nd, 2017

Matthew Harrison Upgraded (SRPT) to Buy on, Oct 2nd, 2017


Published on 2024-10-25 23:06:24 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy on, Oct 2nd, 2017.

Matthew has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months

  • Gena Wang of "Barclays" Initiated at Hold and Held Target at $46 on, Thursday, September 7th, 2017


This is the rating of the analyst that currently disagrees with Matthew

  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017
Contributing Sources